ITonis

ITonis FCF Growth

The Year-over-Year Free Cash Flow Growth of ITonis (ITNS) as of Oct 24, 2026 is -1,248.32 %. In the previous year, Year-over-Year Free Cash Flow Growth was 78.54 % — a change of -1,689.36% (lower).

FCF Growth

-1,248.32 %

YoY

-1,689.36%

Last updated:

Year-over-Year Free Cash Flow Growth of ITonis is 2023 -1,248.32 % . Year-over-Year Free Cash Flow Growth of ITonis was 2022 78.54 % . It decreases by -1,689.36% lower compared to the previous year.

The ITonis FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2016
85.06 USD
Jan 1, 2017
5.62 USD
Jan 1, 2018
-14.92 USD
Jan 1, 2019
34.30 USD
Jan 1, 2020
3.80 USD
Jan 1, 2021
27.42 USD
Jan 1, 2022
78.54 USD
Jan 1, 2023
-1,248.32 USD
The ITonis FCF Growth history
YEARFCF GrowthYoY
-1,248.32 %-1,689.36%
78.54 %+186.44%
27.42 %+621.71%
3.80 %-88.92%
34.30 %-329.96%
-14.92 %-365.32%
5.62 %-93.39%
85.06 %+1,070.63%
7.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ITonis Stock analysis

What does ITonis do? Itonis, Inc. generates revenue through the distribution of its homeopathic anti-nausea product Emesyl to the medical and pharmaceutical industry. The company markets Emesyl, an over-the-counter and prescription homeopathic preparation, primarily targeting the general public suffering from nausea. Sales occur via Amazon and the company's website Emesyl.com. The firm's subsidiaries, Itonis Holdings, Inc. and Paramount Discoveries, Inc., support its operations in the pharmaceutical sector. Emesyl is positioned as a solution for common ailments, with its availability on Amazon and Emesyl.com enabling direct consumer access. The company's focus on both over-the-counter and prescription products allows it to serve diverse customer segments within the healthcare market. Itonis Pharmaceuticals division handles the production and marketing of these homeopathic preparations. The business model relies on the sale of Emesyl through established retail channels and direct online sales, leveraging the brand's presence on Amazon and its dedicated website. This approach targets individuals seeking nausea relief without requiring a prescription, aligning with the product's over-the-counter status and broad market appeal. ITonis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ITonis stock

Year-over-Year Free Cash Flow Growth of ITonis is -1,248.32 % in 2023.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth ITonis since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's ITonis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — ITonis

All Key Metrics — ITonis